Oral Semaglutide Cuts MACE Risk in Type 2 Diabetes
1 day ago · Topline results were announced from a cardiovascular outcomes study evaluating oral semaglutide in patients with type 2 diabetes. The double-blind, placebo-controlled, phase 3 SOUL trial (ClinicalTrials.gov Identifier: NCT03914326) included 9650 patients aged 50 years and older with type 2 diabetes and established cardiovascular disease, and/or chronic kidney disease.
Semaglutide 2.4 mg Reduces All-Cause Hospital Admissions
1 day ago · The mean length of stay was similar between the semaglutide and placebo groups (13.0 vs 13.2 days; P = .76), but the number of days hospitalized per 100 patient years was lower in the semaglutide ...
News details - novonordisk-us.com
About the SELECT trial SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a multicenter, randomized, double-blind, placebo-controlled, event-driven superiority trial designed to evaluate the efficacy of semaglutide 2.4 mg versus placebo as an adjunct to cardiovascular standard of care for reducing ...
New SELECT trial analysis with semaglutide 2.4 mg showed a ...
2 days ago · According to this SELECT analysis, a lower percentage of patients taking semaglutide 2.4 mg experienced a first hospital admission for any indication versus placebo (33.4 vs 36.7%, hazard ratio ...
FDA Approves First Treatment to Reduce Risk of Serious Heart ...
Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults...
Ozempic linked to lower Alzheimer's risk in people with Type ...
Oct 24, 2024 · Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the...
Semaglutide linked to reduced arthritis knee pain in people ...
6 days ago · People who lost a significant amount of weight with semaglutide saw major improvements in osteoarthritis knee pain, research published Wednesday in the New England Journal of Medicine finds.
Ozempic reduces risk of serious illness and death in people ...
May 24, 2024 · Weekly injections of semaglutide medications like Ozempic significantly reduce the risk of serious kidney outcomes, major cardiovascular events and death among people who have type 2 diabetes and...
FDA approves first oral GLP-1 treatment for type 2 diabetes
FDA approves Rybelsus (semaglutide) oral tablets to improve blood sugar in adults with type 2 diabetes, with diet and exercise. It is first GLP-1 receptor protein treatment approved in U.S.
Anti-obesity drug also protects against heart disease — what ...
Aug 10, 2023 · Clinical-trial data suggest that semaglutide, sold under the name Wegovy, slashes risk of heart attacks and other cardiovascular incidents.